 |
|
|
| |
Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir DF in HIV-Infected Virologically Suppressed Older Adults at Week 48:
Subgroup Analysis of a Randomized Switch Study
(Study 311-1089)
|
| |
| |
Reported by Jules Levin
IDWeek 2016 Oct 26-30 New Orleans
Eric S. Daar,1 Joel Gallant,2 Gordon Crofoot,3 Kenneth Lichtenstein,4
Anthony LaMarca,5 Peter Shalit,6 Christopher Lucasti,7 Daniel Coulston,8
Craig Dietz,9 Mingjin Yan,10 Sandra Friborg,10 Martin Rhee10
1Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; 2Southwest CARE Center, Santa Fe, NM; 3Gordon E. Crofoot MD PA, Houston, TX; 4National Jewish Health, Denver, CO; 5Therafirst Medical Center, Fort Lauderdale, FL;
6Peter Shalit and Associates, Seattle, WA; 7South Jersey Infectious Disease, Somers Point, NJ; 8Premier Clinical Research, Spokane, WA; 9Kansas City CARE Clinic, Kansas City, MO; 10Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
